Revelation Biosciences (REVB) has started its PRIME – PReconditioning IMmunostimulatory Evaluation – Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease, or CKD. The US based multi-site placebo-controlled study will enroll up to forty patients in five cohorts of single escalating doses. Top-line data including safety, tolerability, and biomarkers of target activity are expected by mid-year. Data from the PRIME clinical study will support future development in both the GEM-CKD and GEM-AKI programs.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.